DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Medtech (393)

US Opportunities for Alzheimer’s Imaging Agents 2014

The first Alzheimer's imaging agent, Amyvid, became available in the US in April 2012 and, though the market for these products was valued at less than $3 million in 2013, increased coverage and the launch of the first DMT for AD will help the market to experience rapid expansion through 2022.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Alzheimer's imaging agents in the US across a 10-year period.

Questions Answered in This Report:

  • In April 2012, Amyvid became the first Alzheimer's imaging agent available on the US market. Despite the product's ability to aid physicians in arriving at an earlier diagnosis for AD, very few commercial procedures were performed in 2012 and 2013.

    What factors have limited procedure volumes following the product's introduction to the market?

    In which facilities are the majority of these procedures currently being performed?

    What systems are currently being used to perform these procedures, and how will this change over the forecast period?

  • While there was only one product on the market in 2013, a number of competitors, including GE Healthcare, Piramal Enterprises, and Navidea Biopharmaceuticals, are all expected to launch products into the market.

    When is each competitor expected to launch its Alzheimer's imaging agent on the market?

    How will price competition affect the ASP of Alzheimer's imaging agents through 2022?

    What strategies can competitors employ to drive market share gains going forward?

  • Going forward, a number of key events will significantly impact the beta-amyloid imaging market. In addition to the commencement of CED trials, the first DMT for AD will reach the market in 2018.

    What impact will the improved access of beta-amyloid imaging procedures through CED trials have on the market size?

    How will the launch of the first DMT affect referrals for beta-amyloid imaging scans?


Geographies Covered: US

Procedures Covered: DRG's analysis uses the following breakdown of procedures:

Procedure Type

Beta-Amyloid Imaging Procedures

Revenue Type






Facility Type



Other Imaging Procedures

Procedure Type

Magnetic Resonance



Products Covered: DRG's analysis uses the following breakdown of products in the market:

Product Type

Alzheimer's Imaging Agents

Nuclear Medicine Systems




Market Forecast Features: Based on primary research with industry professionals, DRG uses its proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, unit sales, ASPs, installed base, and market values over a 10-year period (2012–2022).

Competitive Analysis: DRG provides a detailed analysis of the competitive landscape and market shares for leading competitors.